-

11:40:00 PM

DARE Stock News

DARE - Dare Bioscience Inc

09/21/23 8:00 AM

Nasdaq : DARE

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational

RHEA-AI

positive

09/20/23 8:00 AM

Nasdaq : DARE

conferences

Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American

RHEA-AI

very positive

09/06/23 8:00 AM

Nasdaq : DARE

conferences

Daré Bioscience to Participate in Upcoming Investor Conferences

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following investor conferences in September 2023: Event: H.C.

RHEA-AI

very positive

09/05/23 8:00 AM

Nasdaq : DARE

Daré Bioscience Completes Previously Announced Equity Financing

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s

RHEA-AI

neutral

08/30/23 8:00 AM

Nasdaq : DARE

offering

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor of one of the company’s early stage

RHEA-AI

neutral

08/10/23 8:00 AM

Nasdaq : DARE

earnings

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)) : XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study – Patient Enrollment to Begin 4Q2023 Sildenafil Cream, 3.6%

RHEA-AI

neutral

08/09/23 8:00 AM

Nasdaq : DARE

clinical trial

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

DARE-HRT1 Demonstrated Preliminary Treatment Efficacy for Both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM) The North American Menopause Society (NAMS) Guidance on Hormone Therapy States that Dosing Estrogen and Progestogen in Combination May Offer Important Benefits to

RHEA-AI

neutral

08/03/23 8:00 AM

Nasdaq : DARE

conferencesearnings

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter

RHEA-AI

very positive

07/31/23 8:00 AM

Nasdaq : DARE

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and Treatment of Idiopathic Preterm Birth Currently no FDA-Approved Product for the Treatment of Preterm Birth SAN DIEGO, July 31, 2023

RHEA-AI

neutral

07/11/23 5:30 PM

Nasdaq : DARE

conferences

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

DARE Data

IndustryPharmaceutical Preparation Manufacturing
Websitedarebioscience.com
Security nameDare Bioscience Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Dare Bioscience Inc

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.